Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

Author： Veltkamp Stephan A.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.31, Iss.12, 2011-12, pp. : 839-851

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, and assessment of dose proportionality in healthy participants

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 4, 2015-07 ,pp. : 279-286

John Wiley & Sons Inc

Access to resources Recommend Favorite

Development of Sodium-Dependent Glucose Co-Transporter 2 Inhibitors as Potential Anti-Diabetic Therapeutics

By  

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 12, 2011-06 ,pp. : 1476-1512

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

By  

Medicinal Chemistry, Vol. 10, Iss. 3, 2014-05 ,pp. : 304-317

Bentham Science Publishers

Access to resources Recommend Favorite

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

By Lamos Elizabeth M   Younk Lisa M   Davis Stephen N  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 6, 2014-06 ,pp. : 875-882

Informa Healthcare

Access to resources Recommend Favorite

Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents

By Washburn William N  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 5, 2012-05 ,pp. : 483-494

Informa Healthcare

Access to resources Recommend Favorite